LP-001

**LP-001 is an ambiguous, non-unique development code and does not identify one chemical entity.** LongBio Pharma uses LP-001 for a long-acting recombinant human erythropoietin fused to an immunoglobulin Fc domain, intended to stimulate erythropoiesis and being clinically studied for myelodysplastic syndromes and anemia-related applications. Separately, Kaizen Bioscience uses LP-001 for an oral pediatric formulation of **amoxicillin + clavulanate**, in which amoxicillin inhibits bacterial cell-wall synthesis and clavulanate inhibits beta-lactamases. These products have different developers, compositions, routes, modalities, mechanisms, and indications and must not be merged into one drug record. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41549777/))